Exploring radiosensitivity predictive factors using body fluid metabolomes for prostate cancer

Exploring radiosensitivity predictive factors using body fluid metabolomes for prostate cancer - Exploring radiosensitivity predictive factors using body fluid metabolomes for prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039216

Enrollment

Registered

2020-01-21

Start date

2020-01-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Twenty years of age or older; patients histologically diagnosed prostate cancer. 2)Patients suitable for curative radiotherapy 3)No history of pelvic radiotherapy

Exclusion criteria

Exclusion criteria: 1)Patients with intractable inflammatory bowel disease 2)Patients with severe liver cirrhosis, diabetes mellitus or cardiovascular diseases 3) Patients with malignancies other than prostate cancer

Design outcomes

Primary

Measure	Time frame
We collected patients' saliva metabolites before, 2 weeks after, and 3 months after the start of radiotherapy, and just after the end of treatment. To search for independent patient-related risk factors for predicting complications using saliva metabolomes.	—

Countries

Japan

Contacts

Public ContactSachika Shiraishi

Toyko Medical University Department of radiology

s-nogi@tokyo-med.ac.jp0333426111

Outcome results